Get the Stockscreener App
0.9569
1.09%
-0.00485
Prelude Therapeutics Inc stock is traded at $0.9569, with a volume of 30,537.
It is down -1.09% in the last 24 hours and down -46.56% over the past month.
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
See More
Previous Close:
$0.9617
Open:
$0.96
24h Volume:
30,537
Relative Volume:
0.09
Market Cap:
$53.38M
Revenue:
-
Net Income/Loss:
$-131.52M
P/E Ratio:
-0.4409
EPS:
-2.17
Net Cash Flow:
$-107.56M
1W Performance:
-7.65%
1M Performance:
-46.56%
6M Performance:
-76.74%
1Y Performance:
-70.55%
1-Day Range:
$0.94
$0.9736
1-Week Range:
$0.931
$1.075
52-Week Range:
$0.931
$6.80
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Name
Prelude Therapeutics Inc
Sector
Industry
Phone
(302) 467-1280
Address
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| PRLD | 0.9512 | 53.38M | 0 | -131.52M | -107.56M | -2.17 |
| VRTX | 447.70 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.19 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.39 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.73 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.22 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-29-22 | Initiated | Jefferies | Buy |
| Mar-15-22 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-28-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-27-21 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-26-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Nov-20-20 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Goldman | Neutral |
| Oct-20-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prelude Therapeutics Inc Stock (PRLD) Latest News
Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD) - MSN
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Update - MarketBeat
Prelude Therapeutics' SWOT analysis: biotech stock faces pivotal data readouts - Investing.com
PRLD Stock Touches 52-Week Low at $1.1 Amid Market Challenges - Investing.com
Prelude Therapeutics (NASDAQ:PRLD) Receives Buy Rating from HC Wainwright - Defense World
Prelude Therapeutics Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Prelude Therapeutics Reports Q3 2024 Results and Clinical Progress - MSN
Prelude Therapeutics (NASDAQ:PRLD) Given "Buy" Rating at HC Wainwright - MarketBeat
Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
PRLD stock touches 52-week low at $1.32 amid market challenges - Investing.com Australia
Prelude Therapeutics’ (PRLD) Buy Rating Reiterated at HC Wainwright - Defense World
PRLD stock touches 52-week low at $1.32 amid market challenges By Investing.com - Investing.com South Africa
Prelude Therapeutics' SWOT analysis: biotech stock faces pivotal data readouts By Investing.com - Investing.com South Africa
Prelude Therapeutics (NASDAQ:PRLD) Receives "Buy" Rating from HC Wainwright - MarketBeat
Prelude Therapeutics price target lowered to $1 from $3 at Barclays - Yahoo Finance
Prelude Therapeutics Shares Promising Phase 1 Trial Data for PRT3789 at International Symposium - MyChesCo
Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium - Yahoo Finance
PRLD stock touches 52-week low at $1.65 amid market challenges - Investing.com India
PRLD stock touches 52-week low at $1.65 amid market challenges By Investing.com - Investing.com South Africa
Deal Watch: Lilly Turns To Oblique For Antibody Discovery - Scrip
Oncopia Therapeutics and University of Michigan divulge new SMARCA2 and SMARCA4 degradation inducers - BioWorld Online
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Sees Significant Decline in Short Interest - MarketBeat
Aprea Therapeutics to Showcase Oncology Advances at Barcelona Symposium - MyChesCo
Prelude Therapeutics Showcases Innovative SMARCA Degrader Programs at Barcelona Symposium - MyChesCo
Prelude Therapeutics shares updates on cancer drug trials By Investing.com - Investing.com Canada
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium - Yahoo Finance
Wall Street today: US stocks trade higher as investors re-evaluate big Fed rate cut potential, Intel Corp. gains 1.83% - MSN
Short Interest in Prelude Therapeutics Incorporated (NASDAQ:PRLD) Increases By 37.0% - MarketBeat
Invesco S&P SmallCap Materials ETF (NASDAQ:PSCM) Short Interest Up 22.6% in September - Defense World
RF Acquisition Corp. (NASDAQ:RFAC) Short Interest Update - Defense World
Squarepoint Ops LLC Grows Stock Holdings in Teleflex Incorporated (NYSE:TFX) - Defense World
Axa S.A. Acquires 1,964 Shares of West Pharmaceutical Services, Inc. (NYSE:WST) - Defense World
Employees Retirement System of Texas Makes New Investment in Nova Ltd. (NASDAQ:NVMI) - Defense World
FDA Issues Draft Guidance on Multiregional Clinical Trials in Oncology - MyChesCo
Firstsource Acquires Ascensos - MENAFN.COM
Firstsource acquires UK-based Ascensos for $56 million - The Economic Times
Angel Capital weaves passage to glory in Guineas Prelude - Horse Betting
Larimar Therapeutics to Present Groundbreaking Nomlabofusp Studies at ICAR Conference - MyChesCo
19 Sundance Movies to Watch Before Seeing These Filmmakers’ New Fall 2024 Releases - Sundance Institute
First Taste: At Prelude, Southern-inspired flavors get the fine-dining spotlight. - 7x7
Prelude Therapeutics (NASDAQ:PRLD) Upgraded to Strong-Buy by HC Wainwright - MarketBeat
Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis - MyChesCo
Data clang on Street for Prelude but SMARCA2 overtures continue - BioWorld Online
Healthy Upside Potential: Prelude Therapeutics Inc (PRLD) - SETE News
Prelude Therapeutics Inc (PRLD) deserves closer scrutiny - US Post News
Prelude Therapeutics (NASDAQ:PRLD) Receives “Market Outperform” Rating from JMP Securities - Defense World
A Closer Look at Prelude Therapeutics Inc (PRLD) Stock Gains - The InvestChronicle
Glioblastoma Treatment Drugs, Pipeline Insights, Emerging Therapies, and Companies 2024 - openPR
We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate - Simply Wall St
Prelude Therapeutics Inc Stock (PRLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):